Article
Targeting C/EBPα overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia.
Nature communications - 5 Apr 2023
Wang Hanlin, Luo Guanghao, Hu Xiaobei, Xu Gaoya, Wang Tao, Liu Minmin, Qiu Xiaohui, Li Jianan, Fu Jingfeng, Feng Bo, Tu Yutong, Kan Weijuan, Wang Chang, Xu Ran, Zhou Yubo, Yang Jianmin, Li Jia
Abstract excerpt
The outcomes of FLT3-ITD acute myeloid leukaemia (AML) have been improved since the approval of FLT3 inhibitors (FLT3i). However, approximately 30-50% of patients exhibit primary resistance (PR) to FLT3i with poorly defined mechanisms, posing a pressing clinical unmet need. Here, we identify C/EBPα activation as a top PR feature by analyzing data from primary AML patient samples in Vizome. C/EBPα activation limit...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.